Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC transplantation in septic shock
NL-OMON39173Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Feb 2013
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Provacel in septic shock (2 arms), sponsored by Erasmus MC. Primary endpoints: Shock-reversal time, Dose of norepinephrine and 1 more. Planned start Feb 2013; status: withdrawn.
02
Drugs
Provacel
03
Conditions
septic shock
Beyond the preview
Go deeper on NL-OMON39173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39173.